Oct 9, 2003
Hi Dr. Young,
Not too long ago, i read fosamprenavir had gone through clinical trials, successfully. It appears to have great efficacy, little side effects (especially for a PI) and the once daily protocol is favorable. Why hasn't it hit the market yet?
| Response from Dr. Young
Fosamprenavir (or 908) is a new HIV protease inhibitor (the follow up to the potent, but unwieldly amprenavir (Agenerase). The maker of fosamprenavir, GlaxoSmithKline has submitted paperwork to the US FDA for review; I expect that we will hear from the FDA any week now about the approval status.
Three large clinical trials have looked at 908 in both therapy naive and therapy-experienced patients; the drug shows a very good profile as a unboosted- or boosted-protease inhibitor. It will certainly increase our treatment options and can be dosed either once- or twice-daily (depending on the situation and whether boosted). In any case, the pill burden will be attractive, with a total (including the boosting Norvir) pill count of 4 per day.
Stay tuned-- BY
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.